Previous 10 | Next 10 |
2023-03-22 17:06:31 ET An FDA advisory panel voted 9-0 that the data on Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) amyotrophic lateral sclerosis (ALS) drug tofersen likely predicts it benefit. The recommendation from the Peripheral and Central...
2023-03-20 11:20:47 ET Veterans living with Alzheimer's disease will have access to Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALF )( OTCPK:ESAIY ) Alzheimer's drug Leqembi (lecanamab) through the Veterans Health Administration. The move is somewhat of a surpris...
2023-03-20 10:49:05 ET Although a pivotal trial failed to meet its primary and second endpoints, data indicates that Biogen's ( NASDAQ: BIIB ) amyotrophic lateral sclerosis (ALS) candidate tofersen may benefit those with the neurodegenerative disease, FDA scientists say. ...
2023-03-19 05:30:00 ET Over time, Biogen (NASDAQ: BIIB) created a true success story. The biotech company built up an impressive portfolio of multiple sclerosis (MS) drugs and generated billions of dollars in earnings. The share price followed, climbing more than 20,000% from its in...
2023-03-16 08:45:38 ET Summary More than likely the Food and Drug Administration will grant full approval to Leqembi in July which should boost Biogen and Eisai's stock value. If the FDA grants full approval, Medicare has indicated that it will expand coverage for the drug. Bi...
2023-03-16 07:01:27 ET Biogen ( NASDAQ: BIIB ) said that the Court of Justice of the EU decided in favor of the company, the European Medicines Agency (EMA), and the European Commission (EC) in their appeal of a General Court decision annulling the EMA's refusal to evalua...
2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision annulling th...
2023-03-15 23:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-14 10:23:00 ET Biogen (NASDAQ: BIIB) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons. U.S. approval of Biogen's Aduhelm for treating Alzheimer's disease (AD) turned out to be a bit of a flop as t...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...